FDA’s IRB Guidance Blurs Lines Between Sponsors And Review Boards, Stakeholders Say
This article was originally published in The Gray Sheet
Executive Summary
FDA’s final guidance on institutional review boards continues to blur areas of responsibility between sponsors and review boards, a complaint raised by stakeholders earlier in the guidance development process.